

Mignon L Loh

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9143829/mignon-l-loh-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

368
papers

19,875
citations

76
h-index

136
g-index

398
ext. papers

23,966
ext. citations

6.3
avg, IF

6.14
L-index

#	Paper	IF	Citations
368	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. <i>Nature</i> , 2012 , 481, 157-63	50.4	1163
367	Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. <i>Nature Genetics</i> , 1999 , 23, 166-75	36.3	897
366	Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. <i>Cancer Cell</i> , 2002 , 1, 75-87	24.3	895
365	Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. <i>New England Journal of Medicine</i> , 2014 , 371, 1005-15	59.2	885
364	Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. <i>Cancer Cell</i> , 2012 , 22, 153-66	24.3	515
363	Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. <i>Science</i> , 2014 , 346, 1373-7	33.3	484
362	The genomic landscape of hypodiploid acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013 , 45, 242-52	36.3	474
361	JAK mutations in high-risk childhood acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 9414-8	11.5	446
360	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2017 , 49, 1211-1218	36.3	430
359	Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. <i>Cancer Research</i> , 2004 , 64, 8816-20	10.1	404
358	Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. <i>Blood</i> , 2004 , 103, 2325-31	2.2	358
357	Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). <i>Blood</i> , 2007 , 109, 926-35	2.2	338
356	Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. <i>Molecular Cell</i> , 2000 , 6, 693-704	17.6	266
355	Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. <i>Nature Genetics</i> , 2010 , 42, 794-800	36.3	257
354	Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. <i>Blood</i> , 2012 , 120, 3510-8	2.2	220
353	Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2380-8	2.2	219
352	Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Blood</i> , 2011 , 118, 3080-7	2.2	218

351	Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. <i>Blood</i> , 2015 , 126, 964-71	2.2	217
350	Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2015 , 6, 6604	17.4	215
349	Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. <i>Blood</i> , 2009 , 114, 1859-63	2.2	212
348	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. <i>Nature Genetics</i> , 2013 , 45, 1494-8	36.3	205
347	Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2011 , 43, 237-41	36.3	201
346	Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. <i>Cancer Cell</i> , 2008 , 14, 335-43	24.3	195
345	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2019 , 51, 296-307	36.3	189
344	Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. <i>Blood</i> , 2006 , 107, 2639-42	2.2	183
343	Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. <i>Blood</i> , 2012 , 119, 3512-22	2.2	181
342	Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 815-23	27.4	179
341	High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. <i>Science Translational Medicine</i> , 2012 , 4, 134ra63	17.5	175
340	Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. <i>Blood</i> , 2017 , 129, 3352-3361	2.2	168
339	Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 733-42	9.7	167
338	The genomic landscape of juvenile myelomonocytic leukemia. <i>Nature Genetics</i> , 2015 , 47, 1326-1333	36.3	166
337	Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. <i>Blood</i> , 2012 , 120, 833-42	2.2	166
336	Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment. <i>Nature</i> , 2016 , 539, 304-308	50.4	154
335	Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. <i>Blood</i> , 2015 , 125, 1759-67	2.2	147
334	Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. <i>Journal of Clinical Oncology</i> , 2007 , 25, 813-9	2.2	147

333	Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. <i>Cancer Discovery</i> , 2014 , 4, 1074-87	24.4	146
332	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2016 , 48, 1481-1489	36.3	145
331	The genetic basis and cell of origin of mixed phenotype acute leukaemia. <i>Nature</i> , 2018 , 562, 373-379	50.4	140
330	Genome-wide study of methotrexate clearance replicates SLCO1B1. <i>Blood</i> , 2013 , 121, 898-904	2.2	137
329	Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. <i>Blood</i> , 2013 , 121, 485-8	2.2	136
328	ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2012 , 30, 751-7	2.2	131
327	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2016 , 7, 13331	17.4	128
326	Philadelphia chromosome-like acute lymphoblastic leukemia. <i>Blood</i> , 2017 , 130, 2064-2072	2.2	125
325	Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. <i>Lancet Oncology</i> , 2015 , 16, 1659-66	21.7	123
324	Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2013 , 60, 957-63	3	121
323	Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2011 , 152, 677-87	4.5	119
322	Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. <i>Leukemia</i> , 2019 , 33, 884-892	10.7	119
321	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2306-2314	2.2	119
320	Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 11306-11311	11.5	117
319	Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2018 , 131, 995-999	2.2	112
318	Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. <i>Clinical Cancer Research</i> , 2014 , 20, 4540-8	12.9	110
317	Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. <i>Blood</i> , 2018 , 131, 1350-1359	2.2	108
316	Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. <i>Blood</i> , 2017 , 129, e26-e37	2.2	107

315	Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. <i>Blood</i> , 2017 , 129, 177-187	2.2	101
314	Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3397-402	2.2	99
313	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2018 , 33, 937-948.e8	24.3	98
312	Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis. <i>Human Molecular Genetics</i> , 2014 , 23, 4315-27	5.6	95
311	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2926-2934	2.2	95
310	Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2016 , 29, 186-200	24.3	92
309	Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. <i>Pediatric Blood and Cancer</i> , 2006 , 46, 579-85	3	91
308	Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. <i>Nature</i> , 2015 , 521, 357-61	50.4	90
307	Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. <i>Blood</i> , 2011 , 118, 2191-9	2.2	89
306	Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. <i>Blood</i> , 2017 , 130, 397-407	2.2	88
305	Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. <i>Blood</i> , 2006 , 107, 4508-13	2.2	87
304	Treatment of infantile fibrosarcoma with chemotherapy and surgery: results from the Dana-Farber Cancer Institute and Children's Hospital, Boston. <i>Journal of Pediatric Hematology/Oncology</i> , 2002 , 24, 722-6	1.2	87
303	TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. <i>Journal of Clinical Oncology</i> , 2018 , 36, 591-599	2.2	85
302	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. <i>Blood</i> , 2015 , 125, 680-6	2.2	84
301	SHP-2 and myeloid malignancies. <i>Current Opinion in Hematology</i> , 2004 , 11, 44-50	3.3	84
300	Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. <i>Blood</i> , 2013 , 121, 1814-8	2.2	82
299	Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. <i>Cancer Cell</i> , 2015 , 27, 409-25	24.3	81
298	Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. <i>Blood</i> , 2013 , 121, 4925-9	2.2	80

297	Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. <i>Pediatric Blood and Cancer</i> , 2010 , 55, 421-9	3	80
296	T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children's Oncology Group (COG) Study AALL0434. <i>Blood</i> , 2014 , 124, 1-1	2.2	80
295	Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3816-23	2.2	79
294	Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia. <i>Blood</i> , 2014 , 124, 2487-97	2.2	76
293	The COVID-19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI, and St Jude Global. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28409	3	74
292	A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). <i>Pediatric Blood and Cancer</i> , 2015 , 62, 1717-24	3	72
291	Prenatal origin of TEL-AML1-positive acute lymphoblastic leukemia in children born in California. <i>Genes Chromosomes and Cancer</i> , 2003 , 37, 36-43	5	68
290	Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. <i>Nature</i> , 2018 , 553, 511-514	50.4	67
289	Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3874-82	2.2	66
288	Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. <i>Pediatric Blood and Cancer</i> , 2015 , 62, 1176-83	3	65
287	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. <i>Blood</i> , 2018 , 132, 815-824	2.2	58
286	Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2133-40	2.2	57
285	Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. <i>Blood</i> , 2015 , 125, 516-24	2.2	56
284	TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches. <i>Current Opinion in Hematology</i> , 2002 , 9, 345-52	3.3	56
283	Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL. <i>Blood Advances</i> , 2017 , 1, 1657-1671	7.8	56
282	Genomic subtyping and therapeutic targeting of acute erythroleukemia. <i>Nature Genetics</i> , 2019 , 51, 694-704	30.3	54
281	Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 833-842	27.4	54
280	Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. <i>Journal of Clinical Oncology</i> , 2020 , 38, 602-612	2.2	52

279	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. <i>Nature Communications</i> , 2015 , 6, 7553	17.4	51
278	Genetic predispositions to childhood leukemia. <i>Therapeutic Advances in Hematology</i> , 2013 , 4, 270-90	5.7	51
277	Improving outcomes for high-risk ALL: translating new discoveries into clinical care. <i>Pediatric Blood and Cancer</i> , 2011 , 56, 984-93	3	51
276	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3282-3293 ²	3.2	51
275	Characterization of leukemias with ETV6-ABL1 fusion. <i>Haematologica</i> , 2016 , 101, 1082-93	6.6	49
274	Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. <i>Leukemia Research</i> , 2005 , 29, 459-62	2.7	49
273	Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1897-1905	2.2	49
272	Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11). <i>Journal of Medicinal Chemistry</i> , 2013 , 56, 7212-21	8.3	48
271	Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. <i>Nature Communications</i> , 2017 , 8, 2127	17.4	47
270	Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. <i>Blood</i> , 2016 , 127, 558-64	2.2	47
269	Advances in the genetics of high-risk childhood B-progenitor acute lymphoblastic leukemia and juvenile myelomonocytic leukemia: implications for therapy. <i>Clinical Cancer Research</i> , 2012 , 18, 2754-67	12.9	46
268	Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients With a Philadelphia Chromosome-Like (Ph-like [or BCR-ABL1-Like]) Signature For Therapeutic Targeting	2.2	45
267	Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study AALL0331. <i>International Journal of Cancer</i> , 2016 , 138, 332-9	7.5	44
266	One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. <i>Pediatric Blood and Cancer</i> , 2009 , 52, 259-62	3	44
265	Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2527-2534	2.2	43
264	A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. <i>Blood</i> , 2009 , 113, 1075-85	2.2	43
263	Ph-like acute lymphoblastic leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2016 , 2016, 561-566	3.1	43
262	Childhood acute lymphoblastic leukemia: Integrating genomics into therapy. <i>Cancer</i> , 2015 , 121, 3577-906.4	6.4	41

261	Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 364-74	6.1	41
260	Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2018 , 32, 2126-2137	10.7	38
259	Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e26873	3	37
258	A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology. <i>Nature Communications</i> , 2016 , 7, 10635	17.4	37
257	Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes. <i>JCI Insight</i> , 2018 , 3,	9.9	37
256	Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantation. <i>Frontiers in Pediatrics</i> , 2014 , 2, 25	3.4	36
255	Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2019 , 79, 2339-2351	10.1	35
254	Congenital leukemia cutis with subsequent development of leukemia. <i>Journal of the American Academy of Dermatology</i> , 2006 , 54, S22-7	4.5	35
253	Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. <i>Haematologica</i> , 2015 , 100, 17-22	6.6	34
252	Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015 , 62, 629-36	3	34
251	A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331. <i>Blood</i> , 2019 , 134, LBA-1-LBA-1	2.2	34
250	Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia. <i>Blood</i> , 2017 , 129, 3000-3008	2.2	33
249	Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2019 , 37, 780-789	2.2	33
248	Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 1738-48	6.1	33
247	SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients. <i>Genes Chromosomes and Cancer</i> , 2008 , 47, 253-9	5	33
246	Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 1125-1137	8.3	32
245	Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e27062	3	31
244	PI3K p110 α uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML. <i>Blood</i> , 2014 , 123, 2838-42	2.2	31

243	Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis. <i>Science Signaling</i> , 2013 , 6, ra21	8.8	31
242	Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. <i>Blood</i> , 2008 , 111, 1124-7	2.2	31
241	Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL. <i>Cancer Discovery</i> , 2019 , 9, 436-451	24.4	31
240	Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. <i>Nature Communications</i> , 2019 , 10, 5348	17.4	29
239	Novel susceptibility variants at the locus for childhood acute lymphoblastic leukemia in Hispanics. <i>Blood</i> , 2019 , 133, 724-729	2.2	29
238	Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells. <i>Leukemia</i> , 2019 , 33, 181-190	10.7	28
237	Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015 , 62, 414-8	3	28
236	A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621. <i>Blood</i> , 2019 , 134, 741-741	2.2	28
235	Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies. <i>Future Oncology</i> , 2018 , 14, 2115-2129	3.6	27
234	Childhood myelodysplastic syndrome: focus on the approach to diagnosis and treatment of juvenile myelomonocytic leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2010 , 2010, 357-62	3.1	27
233	Integration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray study. <i>Cancer Genetics</i> , 2015 , 208, 1-18	2.3	26
232	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2018 , 215, 3094-3114	16.6	26
231	Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). <i>Leukemia</i> , 2018 , 32, 1370-1379	10.7	25
230	Congenital fibrosarcoma of the upper extremity. <i>Plastic and Reconstructive Surgery</i> , 1998 , 102, 1158-62	2.7	24
229	Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies. <i>American Journal of Medical Genetics, Part A</i> , 2020 , 182, 866-876	2.5	24
228	Severe pegaspargase hypersensitivity reaction rates (grade B) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1624-1633	1.9	24
227	Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. <i>Blood</i> , 2019 , 134, 1227-1237	2.2	23
226	Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia. <i>Cancer Research</i> , 2013 , 73, 2540-50	10.1	23

225	A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase. <i>Blood</i> , 2018 , 132, 555-555	2.2	23
224	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3062-3070	2.2	22
223	Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. <i>Cancer Genetics</i> , 2019 , 238, 62-68	2.3	21
222	MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. <i>ELife</i> , 2013 , 2, e00825	8.9	21
221	Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. <i>Blood Advances</i> , 2018 , 2, 529-533	7.8	21
220	Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2700-2707	2.2	20
219	Somatic and Germline Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors. <i>Clinical Cancer Research</i> , 2017 , 23, 1852-1861	12.9	20
218	Chromosome 12p deletions in TEL-AML1 childhood acute lymphoblastic leukemia are associated with retrotransposon elements and occur postnatally. <i>Cancer Research</i> , 2008 , 68, 9935-44	10.1	20
217	Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e26928	3	19
216	Molecular characteristics of a pancreatic adenocarcinoma associated with Shwachman-Diamond syndrome. <i>Pediatric Blood and Cancer</i> , 2013 , 60, 754-60	3	19
215	Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1740-1748	1.9	18
214	Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. <i>Cancer</i> , 2018 , 124, 1150-1159	6.4	18
213	Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. <i>Cancer</i> , 2020 , 126, 593-601	6.4	18
212	Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e27034	3	17
211	CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL). <i>Blood</i> , 2017 , 130, 98-98	2.2	17
210	Precision Medicine in Pediatric Oncology: Translating Genomic Discoveries into Optimized Therapies. <i>Clinical Cancer Research</i> , 2017 , 23, 5329-5338	12.9	16
209	Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra [®]) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children's Oncology Group Study.. <i>Blood</i> , 2005 , 106, 2587-2587	2.2	16
208	Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia. <i>Cancer Science</i> , 2019 , 110, 1931-1946	6.9	15

207	Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children's Oncology Group (COG) study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 10008-10008	2.2	15
206	Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. <i>Cancer</i> , 2018 , 124, 571-579	6.4	15
205	Patients with Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia (ALL) Have High Levels of Minimal Residual Disease (MRD) at the End of induction A Children's Oncology Group (COG) Study.. <i>Blood</i> , 2009 , 114, 9-9	2.2	14
204	Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing. <i>Leukemia</i> , 2020 , 34, 662-666	10.7	14
203	Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. <i>Lancet Haematology,the</i> , 2021 , 8, e55-e66	14.6	14
202	A new system identification approach to identify genetic variants in sequencing studies for a binary phenotype. <i>Human Heredity</i> , 2014 , 78, 104-16	1.1	13
201	Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children's Oncology Group (COG) Study AALL0331. <i>Blood</i> , 2014 , 124, 793-793	2.2	13
200	Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia. <i>Blood</i> , 2021 , 137, 168-177	2.2	13
199	Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. <i>PLoS ONE</i> , 2019 , 14, e0221288	3.7	12
198	Lack of TEL/AML1 fusion in pediatric AML: further evidence for lineage specificity of TEL/AML1. <i>Leukemia Research</i> , 1998 , 22, 461-4	2.7	12
197	Next Generation Transcriptomic Resequencing Identifies Novel Genetic Alterations in High-Risk (HR) Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) HR ALL TARGET Project.. <i>Blood</i> , 2009 , 114, 704-704	2.2	12
196	Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group. <i>Leukemia</i> , 2021 , 35, 3272-3277	10.7	12
195	Enhancer Hijacking Drives Oncogenic Expression in Lineage-Ambiguous Stem Cell Leukemia. <i>Cancer Discovery</i> , 2021 , 11, 2846-2867	24.4	12
194	Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. <i>Haematologica</i> , 2019 , 104, 986-992	6.6	12
193	Mutations in GATA2 are rare in juvenile myelomonocytic leukemia. <i>Blood</i> , 2014 , 123, 1426-7	2.2	11
192	Capizzi-Style Methotrexate with Pegasparagase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434. <i>Blood</i> , 2015 , 126, 794-794	2.2	11
191	KRAS insertion mutations are oncogenic and exhibit distinct functional properties. <i>Nature Communications</i> , 2016 , 7, 10647	17.4	10
190	Translocation (2;8)(p12;q24) associated with a cryptic t(12;21)(p13;q22) TEL/AML1 gene rearrangement in a child with acute lymphoblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2000 , 122, 79-82		10

189	Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study. <i>Blood</i> , 2019 , 134, 2649-2649	2.2	10
188	Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1437-1447	2.2	10
187	Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2628-2638	2.2	9
186	Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia. <i>Pediatric Blood and Cancer</i> , 2019 , 66, e27948	3	9
185	Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Children's Oncology Group (COG) AALL0331. <i>Blood</i> , 2013 , 122, 837-837	2.2	9
184	Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021 , 5, 504-512	7.8	9
183	Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition. <i>Blood</i> , 2015 , 126, 3792-3792	2.2	8
182	Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Haematologica</i> , 2019 , 104, e517-e520	6.6	7
181	International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia. <i>Clinical Cancer Research</i> , 2021 , 27, 158-168	12.9	7
180	Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2020 , 1, 1113-1127	15.4	7
179	Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia. <i>Blood</i> , 2021 , 137, 364-373	2.2	7
178	Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 408-417	9.7	7
177	Dysregulated transcriptional networks in and -rearranged T-ALL. <i>Biomarker Research</i> , 2018 , 6, 27	8	7
176	Generation of a human Juvenile myelomonocytic leukemia iPSC line, CHOPi001-A, with a mutation in CBL. <i>Stem Cell Research</i> , 2018 , 31, 157-160	1.6	6
175	Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2019 , 185, 169-174	4.5	6
174	Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131. <i>Blood</i> , 2018 , 132, 35-35	2.2	6
173	Acute Lymphoblastic Leukemia with Zinc-Finger Protein 384 (ZNF384)-Related Rearrangements: A Retrospective Analysis from the Ponte Di Legno Childhood ALL Working Group. <i>Blood</i> , 2019 , 134, 652-652 ²	2.2	6
172	Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study.. <i>Blood</i> , 2009 , 114, 1580-1580	2.2	6

171	Genomic Characterization and Experimental Modeling Of BCR-ABL1-Like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013 , 122, 232-232	2.2	6
170	Incidence of Allergic Reactions to Pegaspargase (PEG) Administered Intramuscularly Versus Intravenously (IM vs. IV) in Children and Young Adults with High Risk B-Lymphoblastic Leukemia (HR B-ALL): Results of Children's Oncology Group (COG) Studies AALL0232/AALL1131. <i>Blood</i> , 2015 , 126, 1303-1303	2.2	6
169	RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	6
168	Downregulating Notch counteracts Kras-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm. <i>Leukemia</i> , 2019 , 33, 671-685	10.7	6
167	FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. <i>Leukemia</i> , 2021 , 35, 1279-1290	10.7	6
166	Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021 ,	15.9	6
165	Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia. <i>Pediatric Blood and Cancer</i> , 2019 , 66, e27905	3	5
164	Induction Toxicities Are More Frequent in Young Adults Compared to Children Treated on the Children's Oncology Group (COG) First Relapse B-Lymphoblastic Leukemia Clinical Trial AALL1331. <i>Blood</i> , 2018 , 132, 1382-1382	2.2	5
163	In Vivo Efficacy of PI3K Pathway Signaling Inhibition for Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013 , 122, 2672-2672	2.2	5
162	Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013 , 122, 618-618	2.2	5
161	Effect of High-Dose Methotrexate (HD-MTX) Vs Capizzi Methotrexate/Pegaspargase (C-MTX/ASNase) on Osteonecrosis (ON) Incidence in Children and Young Adults with T-Acute Lymphoblastic Leukemia (T-ALL): Results of Children's Oncology Group (COG) Study AALL0434. <i>Blood</i> , 2014 , 124, 3649-3649	2.2	5
160	Treatment-Related Mortality (TRM) in Children with Down Syndrome (DS) and B-Lymphoblastic Leukemia (B-ALL): An Interim Report from the Children's Oncology Group Trials AALL0932 and AALL1131. <i>Blood</i> , 2015 , 126, 2502-2502	2.2	5
159	BCL-2, a Therapeutic Target for High Risk Hypodiploid B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016 , 128, 280-280	2.2	5
158	Genome-Wide Association Study of Susceptibility Loci for TCF3-PBX1 Acute Lymphoblastic Leukemia in Children. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 933-937	9.7	5
157	Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium. <i>Blood</i> , 2021 ,	2.2	5
156	Case report: Impact of BITE on CAR-T cell expansion. <i>Advances in Cell and Gene Therapy</i> , 2019 , 2, e50	1.2	4
155	The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia. <i>Molecular Cancer Research</i> , 2020 , 18, 1153-1165	6.6	4
154	Using genomics to define pediatric blood cancers and inform practice. <i>Hematology American Society of Hematology Education Program</i> , 2018 , 2018, 286-300	3.1	4

153	FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study. <i>Blood</i> , 2019 , 134, 1293-1293	2.2	4
152	Mutations in the RAS Signaling, B-Cell Development, TP53/RB1, and JAK Signaling Pathways Are Common in High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project.. <i>Blood</i> , 2009 , 114, 85-85	2.2	4
151	Thymic Stromal Lymphopoietin Stimulation of Pediatric Acute Lymphoblastic Leukemias with CRLF2 Alterations Induces JAK/STAT and PI3K Phosphosignaling. <i>Blood</i> , 2010 , 116, 410-410	2.2	4
150	Continuous Dose Dasatinib Is Safe and Feasible in Combination with Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Children's Oncology Group (COG) Trial AALL0622. <i>Blood</i> , 2012 , 120, 137-137	2.2	4
149	Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome. <i>Blood</i> , 2013 , 122, 825-825	2.2	4
148	Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2015 , 126, 807-807	2.2	4
147	IKZF1 and 22q11.22 Deletions and PDGFRA Gains Are Associated with Poor Outcome in Down Syndrome Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012 , 120, 289-289	2.2	4
146	Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug Resistance. <i>Cancer Research</i> , 2020 , 80, 5189-5202	10.1	4
145	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 794-802	6.1	4
144	Favorable Trisomies and Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1540-1552	2.2	4
143	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Cancer Discovery</i> , 2021 , 11, 1424-1439	24.4	4
142	High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL. <i>SLAS Discovery</i> , 2018 , 23, 732-741	3.4	4
141	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. <i>Pediatric Blood and Cancer</i> , 2019 , 66, e27681	3	3
140	Germline mutations are not associated with Noonan syndrome. <i>Journal of Medical Genetics</i> , 2016 , 53, 728	5.8	3
139	Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101693	2.2	3
138	Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia. <i>Blood</i> , 2018 , 132, 1405-1405	3	3
137	Safety of Palbociclib in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoma: A Children's Oncology Group Pilot Study. <i>Blood</i> , 2020 , 136, 20-21	2.2	3
136	Factors Influencing Survival after Relapse from Childhood ALL: A Children's Oncology Group Study.. <i>Blood</i> , 2006 , 108, 1855-1855	2.2	3

135	Genome-Wide Analysis of Genetic Alterations In Hypodiploid Acute Lymphoblastic Leukemia Identifies a High Frequency of Mutations Targeting the IKAROS Gene Family and Ras Signaling. <i>Blood</i> , 2010 , 116, 411-411	2.2	3
134	Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232. <i>Blood</i> , 2011 , 118, 1440-1440	2.2	3
133	GATA2 Mutations In Pediatric Myelodysplastic Syndromes and Bone Marrow Failure. <i>Blood</i> , 2013 , 122, 1520-1520	2.2	3
132	Comparison Of Mutational Profiles Of Diagnosis and Relapsed Pediatric B-Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. <i>Blood</i> , 2013 , 122, 824-824	2.2	3
131	Phase Ib Trial of the mTOR Inhibitor Everolimus Given in Combination with Multiagent Chemotherapy in Relapsed Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 3765-3765	2.2	3
130	The Genomic Landscape of Childhood T-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 691-691	2.2	3
129	Anti-Pegaspargase, Anti-Calaspargase Pegol , and Anti-Polyethelene Glycol Antibody Incidence in High Risk Acute Lymphoblastic Leukemia Patients Receiving Pegaspargase or Calaspargase Pegol and Associated Anaphylactic or Hypersensitivity Reaction Rates: Results from Children's Oncology Group (COG) Study AALL07P4. <i>Blood</i> , 2016 , 128, 3965-3965	2.2	3
128	Outcomes of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Based on Blast Genotype at Diagnosis: A Report from the Children's Oncology Group. <i>Blood</i> , 2016 , 128, 451-451	2.2	3
127	Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia. <i>Blood</i> , 2016 , 128, 454-454	2.2	3
126	Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731. <i>Blood</i> , 2021 , 138, 2304-2304	2.2	3
125	Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. <i>Haematologica</i> , 2020 , Online ahead of print,	6.6	3
124	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102678	2.2	3
123	Klinefelter syndrome and 47,XYX syndrome in children with B cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2017 , 179, 843-846	4.5	2
122	JAK2 V617F positive polycythemia Vera in a child with neurofibromatosis type I. <i>Pediatric Blood and Cancer</i> , 2008 , 51, 689-91	3	2
121	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Blood</i> , 2018 , 132, 261-261	2.2	2
120	Pharmacokinetics (PK) Substudy of Rituximab in a Prospective Clinical Trial for Pediatric Chronic Immune Thrombocytopenic Purpura (cITP).. <i>Blood</i> , 2005 , 106, 1243-1243	2.2	2
119	Large Regions of Uniparental Disomy (UPD) Establish Clonal Hematopoietic Stem Cell Selection in a Subset of Myelodysplastic Syndrome (MDS) Patients with Normal Bone Marrow Cell Karyotypes.. <i>Blood</i> , 2007 , 110, 120-120	2.2	2
118	A Novel Assay for Juvenile Myelomonocytic Leukemia Based on Aberrant Signaling Networks Measured Via Phospho-Specific Flow Cytometry Reduces Diagnosis Time from Weeks to Days.. <i>Blood</i> , 2007 , 110, 546-546	2.2	2

117	Lack of Somatic Sequence Mutations In Protein Tyrosine Kinase Genes Other Than the JAK Kinase Family In High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project. <i>Blood</i> , 2010 , 116, 2752-2752	2.2	2
116	High-Throughput Screening by Flow Cytometry Identifies Reduced Expression of CD48 As a Universal Characteristic of T-ALL and a Suitable Target for Minimal Residual Disease (MRD) Detection. <i>Blood</i> , 2011 , 118, 2547-2547	2.2	2
115	Functional Analysis of Kinase-Activating Fusions in Ph-like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014 , 124, 786-786	2.2	2
114	Potent Efficacy of Combined PI3K/mTOR and JAK or SRC/ABL Inhibition in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 798-798	2.2	2
113	Residual Disease Monitoring By High Throughput Sequencing Provides Risk Stratification in Childhood B-ALL and Identifies a Novel Subset of Patients Having Poor Outcome. <i>Blood</i> , 2016 , 128, 1086-1086	2.2	2
112	The Genomic Landscape of Childhood and Adult Acute Erythroid Leukemia. <i>Blood</i> , 2016 , 128, 39-39	2.2	2
111	Identification of Novel LNK Mutations In Patients with Chronic Myeloproliferative Neoplasms and Related Disorders. <i>Blood</i> , 2010 , 116, 315-315	2.2	2
110	Pediatric MDS: GATA screen the germline. <i>Blood</i> , 2016 , 127, 1377-8	2.2	2
109	Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations. <i>Blood</i> , 2021 , 137, 1550-1552	2.2	2
108	The T681I mutation is highly resistant to imatinib and dasatinib and detectable in clinical samples prior to treatment. <i>Haematologica</i> , 2021 , 106, 2242-2245	6.6	2
107	Characterization of PAX5-driven Subtypes in B-progenitor Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, S183	2	2
106	Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2021 , 7, 1521-1528	13.4	2
105	Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report.. <i>Cancer</i> , 2022 ,	6.4	2
104	Reply to I.J. Cohen. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3989-3991	2.2	1
103	Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). <i>Leukemia</i> , 2017 ,	10.7	1
102	Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2020 , 136, 44-45	2.2	1
101	Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL). <i>Blood</i> , 2018 , 132, 1000-1000	2.2	1
100	Cytogenetic Subgroups Drive Risk Stratification and Response to Chemotherapy and Blinatumomab in Children and Young Adults with Relapsed B-ALL: A Children's Oncology Group Study. <i>Blood</i> , 2020 , 136, 16-17	2.2	1

99	PTPN11 Mutational Spectrum in Juvenile Myelomonocytic Leukemia and Noonan Syndrome.. <i>Blood</i> , 2004 , 104, 3417-3417	2.2	1
98	Development of an Allele-Specific Minimal Residual Disease Assay for Patients with Juvenile Myelomonocytic Leukemia-Moving beyond Clinical Assessment.. <i>Blood</i> , 2006 , 108, 2681-2681	2.2	1
97	Germline Mutations in CBL Cause a Predisposition to Juvenile Myelomonocytic Leukemia.. <i>Blood</i> , 2009 , 114, 310-310	2.2	1
96	Adjuvant CD49d Blockade Eradicates Chemoresistant ALL. <i>Blood</i> , 2010 , 116, 869-869	2.2	1
95	A BCR-ABL1-Like Gene Expression Profile Confers a Poor Prognosis In Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From Children's Oncology Group (COG) AALL0232. <i>Blood</i> , 2011 , 118, 743-743	2.2	1
94	A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1.. <i>Blood</i> , 2012 , 120, 2466-2466	2.2	1
93	Identification of CRLF2 Genomic Lesions in Patients with Pediatric B-Precursor Acute Lymphoblastic Leukemia (BCP ALL) by Flow Cytometry or Quantitative RT-PCR: A Children's Oncology Group (COG) Stud.. <i>Blood</i> , 2012 , 120, 2529-2529	2.2	1
92	Robust Detection Of Minimal Residual Disease In Unselected Patients With B-Cell Precursor Acute Lymphoblastic Leukemia By High-Throughput Sequencing Of IGH. <i>Blood</i> , 2013 , 122, 2550-2550	2.2	1
91	Genome-Wide DNA Methylation Analysis Reveals Biological and Clinical Insights In Relapsed Childhood Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. <i>Blood</i> , 2013 , 122, 3736-3736	2.2	1
90	Potential Role Of RUNX1 In The Pathogenesis Of Juvenile Myelomonocytic Leukemia (JMML). <i>Blood</i> , 2013 , 122, 45-45	2.2	1
89	HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013 , 122, 60-60	2.2	1
88	Glutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis. <i>Blood</i> , 2014 , 124, 367-367	2.2	1
87	Identifying Drug-Resistant Mutations in Ebf1-Pdgfrb Ph-like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 1423-1423	2.2	1
86	Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015 , 126, 693-693	2.2	1
85	Mixed Lineage Leukemia Rearrangements (MLL-R) Are Determinants of High Risk Disease in Homeobox A (HOXA)-deregulated T-Lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>Blood</i> , 2015 , 126, 694-694	2.2	1
84	Comprehensive Functional Characterization of Germline ETV6 Variants Associated with Inherited Predisposition to Acute Lymphoblastic Leukemia in Children. <i>Blood</i> , 2016 , 128, 1085-1085	2.2	1
83	PRC2 Mutations Induce Resistance to Conventional Chemotherapy By Inhibiting Mitochondrial Apoptosis in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016 , 128, 604-604	2.2	1
82	Minimal Residual Disease Assessment of Remission after Induction Therapy Is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2016 , 128, 758-758	2.2	1

81	A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331. <i>Blood</i> , 2021 , 138, 363-363	2.2	1
80	MEK Inhibition Demonstrates Activity in Relapsed, Refractory Patients with Juvenile Myelomonocytic Leukemia: Results from COG Study ADVL1521. <i>Blood</i> , 2021 , 138, 3679-3679	2.2	1
79	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732. <i>Blood</i> , 2021 , 138, 3398-3398	2.2	1
78	Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children's Oncology Group (COG) Study. <i>Blood</i> , 2021 , 138, 211-211	2.2	1
77	Efficacy of ALL Therapy for WHO2016-Defined Mixed Phenotype Acute Leukemia: A Report from the Children's Oncology Group. <i>Blood</i> , 2017 , 130, 883-883	2.2	1
76	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018 , 132, 565-565	2.2	1
75	Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018 , 132, 4026-4026	2.2	1
74	Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI) standard-risk (SR) B-lymphoblastic leukemia (B-ALL): A report from Children's Oncology Group (COG) AALL0932.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 10509-10509	2.2	1
73	Characterization of Leukemias with ETV6-ABL1 Fusion. <i>Blood</i> , 2015 , 126, 84-84	2.2	1
72	Amplification of AML1 Does Not Impact Early Outcome of Children with Acute Lymphoblastic Leukemia (ALL) Treated with Risk-Directed Chemotherapy: A Report From the Children's Oncology Group (COG).. <i>Blood</i> , 2009 , 114, 2598-2598	2.2	1
71	Nelarabine May Be Safely Incorporated Into a Phase III Study for Newly Diagnosed T-Lineage Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Blood</i> , 2010 , 116, 865-865	2.2	1
70	iAMP21 Is Associated with Inferior Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) on Contemporary Children's Oncology Group (COG) Studies. <i>Blood</i> , 2011 , 118, 739-739	2.2	1
69	Genomic- and Transcriptomic Profiling Of Acute Lymphoblastic Leukemia With Dicentric Chromosomes. <i>Blood</i> , 2013 , 122, 234-234	2.2	1
68	Exploring the genetic and epigenetic origins of juvenile myelomonocytic leukemia using newborn screening samples. <i>Leukemia</i> , 2021 ,	10.7	1
67	Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma. <i>Blood Advances</i> , 2021 , 5, 2890-2900	7.8	1
66	SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome. <i>Blood</i> , 2021 , 137, 1835-1838	2.2	1
65	Aurora A kinase as a target for therapy in rearranged acute lymphoblastic leukemia. <i>Haematologica</i> , 2021 , 106, 2990-2994	6.6	1
64	Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment. <i>Blood Advances</i> , 2021 , 5, 4783-4793	7.8	1

63	A simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemia. <i>Blood Advances</i> , 2021 ,	7.8	1
62	Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy. <i>Blood</i> , 2020 , 136, 37-38	2.2	0
61	Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation.. <i>Nature Genetics</i> , 2022 , 54, 170-179	36.3	0
60	RUNX2 Regulates Cell Migration in T-Cell Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019 , 134, 3947-3947	2.2	0
59	Whole Exome Sequencing of Pediatric Acute Lymphoblastic Leukemia Patients Identify Mutations in 11 Pathways: A Report from the Children's Oncology Group. <i>Blood</i> , 2016 , 128, 455-455	2.2	0
58	Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. <i>Blood</i> , 2012 , 120, 877-877	2.2	0
57	Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e28929	3	0
56	Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia. <i>Blood Advances</i> , 2021 , 5, 3587-3591	7.8	0
55	A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2020 , 136, 47-47	2.2	
54	Genetic Alterations Precede DNA Methylation Changes in Juvenile Myelomonocytic Leukemia. <i>Blood</i> , 2020 , 136, 19-20	2.2	
53	Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report. <i>Blood</i> , 2020 , 136, 39-40	2.2	
52	Sex-Based Disparities in Outcome in Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group (COG) Report. <i>Blood</i> , 2020 , 136, 38-39	2.2	
51	Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report. <i>Blood</i> , 2021 , 138, 2382-2382	2.2	
50	Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021 , 138, 3487-3487	2.2	
49	The Impact of Genetic Ancestry on the Biology and Prognosis of Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021 , 138, 3476-3476	2.2	
48	CD22 low/Bcl-2 high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021 , 138, 614-614	2.2	
47	Functional Analysis of Leukemia-Associated PTPN11 Mutations in Primary Hematopoietic Cells.. <i>Blood</i> , 2004 , 104, 2423-2423	2.2	
46	Cytogenetics of Hispanics and Whites with Childhood Acute Lymphoblastic Leukemia in California.. <i>Blood</i> , 2005 , 106, 4536-4536	2.2	

- 45 Early Response to Therapy Is Significantly Associated with Genetic Subtype of Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group.. *Blood*, **2007**, 110, 758-758 2.2
- 44 Retrospective Survey of Children Treated for Relapsed Acute Lymphoblastic Leukemia (Complete Remission (CR) Rates): A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.. *Blood*, **2007**, 110, 854-854 2.2
- 43 Bcl11a Causes p21Cip1 Down-Regulation and Transplantable Leukemia in Nf1-Deficient Mice.. *Blood*, **2007**, 110, 2657-2657 2.2
- 42 A Rare Case of JAK2 V617F Positive Polycythemia Vera in a Child with Neurofibromatosis Type I.. *Blood*, **2007**, 110, 4661-4661 2.2
- 41 Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Children and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated at Investigator Discretion: A Report from Children's Oncology Group (COG) AALL0434. *Blood*, **2018**, 132, 659-659 2.2
- 40 Identification of New Risk Loci and Regulatory Mechanisms Influencing Genetic Susceptibility to Acute Lymphoblastic Leukaemia. *Blood*, **2019**, 134, 650-650 2.2
- 39 DNA Methylation As a Biomarker of Outcome in JMML: An International Effort Towards Clinical Implementation. *Blood*, **2019**, 134, 1693-1693 2.2
- 38 Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in *Pseudomonas Fluorescens* (RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to *Escherichia coli*-Derived Asparaginases. *Blood*, **2019**, 134, 2586-2586 2.2
- 37 Subclonal Mutations in SETBP1 Predict Relapse in Juvenile Myelomonocytic Leukemia. *Blood*, **2014**, 124, 410-410 2.2
- 36 Deciphering the Epigenetic Landscape of Relapsed Pediatric Acute Lymphoblastic Leukemia. *Blood*, **2014**, 124, 612-612 2.2
- 35 Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. *Blood*, **2014**, 124, 63-63 2.2
- 34 BCL6 Enables RAS-Mediated Pre-B Cell Transformation in Childhood Acute Lymphoblastic Leukemia. *Blood*, **2014**, 124, 3570-3570 2.2
- 33 Cryptic Truncating Rearrangements of the Erythropoietin Receptor in Ph-like Acute Lymphoblastic Leukemia. *Blood*, **2014**, 124, 128-128 2.2
- 32 Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic Leukemia. *Blood*, **2014**, 124, 284-284 2.2
- 31 Biochemical and Functional Analysis of Novel KRAS Insertions in MPN and Other Cancers. *Blood*, **2014**, 124, 2207-2207 2.2
- 30 CbLY371H Transgene Combined with Hematopoietic Deletion of the Endogenous c-Cbl Gene Results in GM-CSF Hypersensitivity and Leukocytosis. *Blood*, **2015**, 126, 3672-3672 2.2
- 29 Germline Genetic Variation in ETV6 and Predisposition to Childhood Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 695-695 2.2
- 28 Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia. *Blood*, **2015**, 126, 556-556 2.2

27	Integrated Genomic Analysis of Down Syndrome Acute Lymphoblastic Leukemia Reveals Recurrent Cancer Gene Alterations and Evidence of Frequent Subclonal Driver Events. <i>Blood</i> , 2016 , 128, 4083-4083 ^{2,2}	
26	New Insights into Deregulated Gene Expression Pathways in MLL- and AF10-Rearranged T-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016 , 128, 2906-2906	2.2
25	Improved Diagnosis of Intrachromosomal Amplification of Chromosome 21 (iAMP21) By Copy Number Profiling. <i>Blood</i> , 2016 , 128, 1733-1733	2.2
24	RUNX1 Is a Candidate Transcriptional Effector in Juvenile Myelomonocytic Leukemia. <i>Blood</i> , 2016 , 128, 2699-2699	2.2
23	Measurement of Phosphorylated ERK As a Prognostic and Predictive Marker for MEK Inhibition in Pediatric B-Lymphoblastic Leukemia: A Pilot Study. <i>Blood</i> , 2016 , 128, 1739-1739	2.2
22	Kinase-Activating Fusions in Pediatric High-Risk B-Lineage Acute Lymphoblastic Leukemia (ALL): a Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium. <i>Blood</i> , 2016 , 128, 1729-1729	2.2
21	Identification of Novel Cluster Groups in High-Risk Pediatric B-Precursor Acute Lymphoblastic Leukemia (HR-ALL) by Gene Expression Profiling: Correlation with Clinical and Outcome Variables. a Children's Oncology Group (COG) Study.. <i>Blood</i> , 2008 , 112, 2256-2256	2.2
20	Quantitative RT-PCR for Expression of a Small Subset of Genes Identifies Novel Prognostic Subgroups in High-Risk Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia (HR-ALL): Clinical Applicability of Gene Expression Microarray Data from Children's Oncology Group Trials.. <i>Blood</i> , 2008 , 112, 1711-1711	2.2
19	Early Response Characteristics and Blast Cytogenetic FEatures In 5,377 Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): A Children's Oncology Group (COG) Study. <i>Blood</i> , 2010 , 116, 414-414	2.2
18	Overcoming Drug Resistance In Acute Lymphoblastic Leukemia by Inhibition of CBP/ECatenin. <i>Blood</i> , 2010 , 116, 3264-3264	2.2
17	ARID5B Genetic Polymorphisms Contribute to Racial Disparities In Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>Blood</i> , 2010 , 116, 8-8	2.2
16	Targeting Survivin In Recalcitrant Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010 , 116, 3263-3263	2.2
15	Targeting mTOR Signaling Is An Effective Treatment Strategy for IKAROS and JAK Kinase Mutated Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010 , 116, 3251-3251	2.2
14	Targeting mTOR and JAK2 in Xenograft Models of CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2011 , 118, 249-249	2.2
13	Novel Chromosomal Rearrangements and Sequence Mutations in High-Risk Ph-Like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2011 , 118, 67-67	2.2
12	Patient-Derived Induced Pluripotent Stem Cells Recapitulate Hematopoietic Abnormalities of Juvenile Myelomonocytic Leukemia. <i>Blood</i> , 2011 , 118, 637-637	2.2
11	Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. <i>Blood</i> , 2011 , 118, 68-68	2.2
10	High-Throughput Sequencing of T-Cell Receptor Gene Loci for Minimal Residual Disease Monitoring in T Lymphoblastic Leukemia. <i>Blood</i> , 2011 , 118, 2545-2545	2.2

- 9 Clinical Spectrum of RAS-Associated Autoimmune Leukoproliferative Disorder (RALD): A Distinct Clinical Entity Mimicking Juvenile Myelomonocytic Leukemia (JMML) or Chronic Myelomonocytic Leukemia (CMML). *Blood*, **2012**, 120, 1033-1033 2.2
- 8 Comparison of High-Throughput Sequencing and Flow Cytometry for Measuring Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Children's Oncology Group Cohort. *Blood*, **2012**, 120, 1440-1440 2.2
- 7 Genome-Wide Association Study Identifies Germline Polymorphisms Associated with Relapse of Childhood Acute Lymphoblastic Leukemia. *Blood*, **2012**, 120, 878-878 2.2
- 6 Expression Profiling for MEIS1 and HOXA9/10 Identifies an Increased Incidence of MLL Rearrangements in T-ALL: A Children's Oncology Group Study.. *Blood*, **2012**, 120, 2505-2505 2.2
- 5 Risk Factors For Acute Pancreatitis In Patients With Acute Lymphoblastic Leukemia. *Blood*, **2013**, 122, 3868-3868 2.2
- 4 Mutations In GATA2 Are Rare In Juvenile Myelomonocytic Leukemia. *Blood*, **2013**, 122, 1526-1526 2.2
- 3 On-Going Evolution Of IGH In B-Cell Precursor Acute Lymphoblastic Leukemia Does Not Substantially Affect Day 29, Post-Treatment MRD Quantification By High-Throughput Sequencing. *Blood*, **2013**, 122, 1341-1341 2.2
- 2 Overexpression Of Leukemia Associated CblY371H Mutation In Transgenic Mice Causes Dosage Dependent Embryonic Lethality. *Blood*, **2013**, 122, 2515-2515 2.2
- 1 Leukemic Blasts With The PNH Phenotype: Correlation With Cytogenetics In ALL. *Blood*, **2013**, 122, 2628-2628 2.2